^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SNS-301

    i
    Other names: PAN-301-1, HAAH-1λ, PAN 301-1, nanoparticle HAAH vaccine, SNS-301
    Company:
    Sensei Biotherap
    Drug class:
    Immunostimulant
    Related drugs:
    over4years
    [VIRTUAL] SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head & neck (SCCHN) (ESMO 2020)
    Pts are required to have ASPH+ SCCHN, actively receiving pembrolizumab or nivolumab for ≥12 weeks, & have a best response of stable disease (SD) or first evidence of progressive disease (PD). Funding: Sensei Biotherapeutics, Inc. Clinical trial identification: NCT04034225; July 16, 2019.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • SNS-301
    over4years
    [VIRTUAL] Safety/efficacy of a phase I/II study of SNS-301 added to pembrolizumab in patients with ASPH+ locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN). (ASCO 2020)
    Anti-PD-1 antibodies such as pembrolizumab and nivolumab can induce durable clinical responses in 13-16% SCCHN patients. Early safety/efficacy warrant further evaluation of this combination therapy. Trial will be proceeding to full enrollment after the safety run-in is completed. Research Funding: None
    Clinical • P1/2 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • SNS-301